Meeting
2014 ASCO Annual Meeting
Adding VEGFR-TKIs to chemotherapy and/or hormonal therapy in advanced breast cancer patients: Results of a meta-analysis.
Authors
Yucai Wang
Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ
Yucai Wang , Zexing Wang , Victor Tsu-Shih Chang , Xiaoxiang Guan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1052)
DOI
10.1200/jco.2014.32.15_suppl.1052
Abstract #
1052
Poster Bd #
145
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.
First Author: Nagi S. El Saghir
Poster
2013 ASCO Annual Meeting
Multitargeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
First Author: Wenhua Liang
Poster
2023 ASCO Annual Meeting
Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC).
First Author: David Graham
Poster
2022 ASCO Quality Care Symposium
Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).
First Author: Emily J. Gallagher